PIK3CD and neoplasm: These imidazobenzoxazepin derivatives (308, PI3Kα IC50~ 0.1- 21.1 nM) had better tumor growth inhibition in vivo, and GDC-0032 (309, PI3Kα/β/δ/γ IC50=0.29/9.1/ 0.12/ 0.97 nM) was identified, which was undergoing clinical development for use in PI3K-related cancers.